The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases. The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies. The panel discusses treatment sequencing after CAR-T or transplant and the role bispecifics and other regimens may play. The panel discusses combination therapy options for patients with DLBCL and FL. The panel discusses novel treatment options for FL, including bispecifics, CAR-Ts, monoclonal antibodies, and more. The panel talks about novel therapies for DLBCL, including the timing and sequencing for such treatments and more. The panel discusses barriers to improving treatment options for patients with DLBCL and follicular lymphoma. A panel discusses the unmet needs and emerging therapeutic areas for DLBCL and follicular lymphoma.